Mechanism of the inhibition of the STAT3 signaling pathway by EGCG

Oncology Reports

Volumn 30, Issue 6, 2013, Pages 2691-2696

  Wang, Yang ^a   Ren, Xuequn ^a   Deng, Chaoyang ^b   Yang, Lu ^b   Yan, Erfu ^c   Guo, Tao ^d   Li, Yanmin ^e   Xu, Marvin Xuejun ^f  

^a HENAN UNIVERSITY   (China)

^b Shanghai Televector Biomedical Ltd Co   (China)

^c TIANJIN UNIVERSITY   (China)

^d SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^e SHANGQIU NORMAL UNIVERSITY   (China)

^f ZHENGZHOU UNIVERSITY   (China)

Author keywords

Epigallocatechin 3 gallate; Hepatocellular carcinoma; Molecular docking; Signal transducer and activator of transcription 3

Indexed keywords

CYCLIN D1; EPIGALLOCATECHIN GALLATE; MYC PROTEIN; PROTEIN BCL XL; STAT3 PROTEIN; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; COMPUTER MODEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LIVER CELL CARCINOMA; MOLECULAR DOCKING; MOLECULAR MECHANICS; MTT ASSAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CATECHIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MOLECULAR DOCKING SIMULATION; PHOSPHORYLATION; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; STAT3 TRANSCRIPTION FACTOR; SURFACE PLASMON RESONANCE; TEA;

EID: 84892421149     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2743     Document Type: Article

References (23)

1. Darnell JE Jr, Kerr IM and Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421, 1994.
2. Buettner R, Mora LB and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954, 2002.
3. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, Sung B and Ichikawa H: Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann NY Acad Sci 1091: 151-169, 2006.
4. Redell MS and Tweardy DJ: Targeting transcription factors in cancer: challenges and evolving strategies. Drug Discov Today Technol 3: 261-267, 2006.
5. Whittaker S, Marais R and Zhu AX: The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29: 4989-5005, 2010.
6. Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald WL, Bornmann W and Bromberg JF: Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 9: R32, 2007.
7. Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, Zasloff M, Marshall JL, Shetty K, Johnson L, Mishra L and He AR: The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling. Oncogene 28: 961-972, 2009.
8. Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N and Montalto G: Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 12: 2563-2568, 2006.
9. Berasin C, Castillo J, Perugorria MJ, Latasa MU, Prieto J and Avila MA: Inflammation and liver cancer: new molecular links. Ann NY Acad Sci 1155: 206-221, 2009.
10. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM and Thorgeirsson SS: Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130: 1117-1128, 2006.
11. To KF, Chan MW, Leung WK, Ng EK, Yu J, Bai AH, Lo AW, Chu SH, Tong JH, Lo KW, Sung JJ and Chan FK: Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line. Br J Cancer 91: 1335-1341, 2004.
12. Li HC, Yashiki S, Sonoda J, Lou H, Ghosh SK, Byrnes JJ, Lema C, Fujiyoshi T, Karasuyama M and Sonoda S: Green tea polyphenoles induce apoptosis in vitro in peripheral blood T lymphocytes of adult T-cell leukemia patients. Jpn J Cancer Res 91: 34-40, 2000.
13. Park G, Yoon BS, Moon JH, Kim B, Jun EK, Oh S, Kim H, Song HJ, Noh JY, Oh C and You S: Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway. J Invest Dermatol 128: 2429-2441, 2008.
14. Ahn HY, Hadizadeh KR, Seul C, Yun YP, Vetter H and Sachinidis A: Epigallocathechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cells. Mol Biol Cell 10: 1093-1104, 1999.
15. Xu X, Kasembeli MM, Jiang X, Tweardy BJ and Tweardy DJ: Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One 4: e4783, 2009.
16. Kasembeli MM, Xu X and Tweardy DJ: SH2 domain binding to phosphopeptide ligands: potential for drug targeting. Front Biosci 14: 1010-1022, 2009.
17. Shao H, Xu X, Jing N and Tweardy DJ: Unique structural determinants for Stat3 recruitment and activation by the granulocyte colony-stimulating factor receptor at phosphotyrosine ligands 704 and 744. J Immunol 176: 2933-2941, 2006.
18. Shao H, Xu X, Mastrangelo MA, Jing N, Cook RG, Legge GB and Tweardy DJ: Structural requirements for signal transducer and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif. J Biol Chem 279: 18967-18973, 2004.
19. Takada M, Nakamura Y, Koizumi T, Toyama H, Kamigaki T, Suzuki Y, Takeyama Y and Kuroda Y: Suppression of human pancreatic carcinoma cell growth and invasion by epigallocatechin-3-gallate. Pancreas 25: 45-48, 2002.
20. Zhu B, Chen H, Zhan W, Wang CY, Cai SR, Wang Z, Zhang CH and He YL: (-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer. World J Gastroenterol 7: 2315-2325, 2011.
21. Yang GY, Liao J, Kim K, Yurkow EJ and Yang CS: Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19: 611-616, 1998.
22. Yang CS, Lambert JD, Hou Z, Ju J, Lu G and Hao X: Molecular targets for the cancer preventive activity of tea polyphenols. Mol Carcinog 45: 431-435, 2006.
23. Shankar S, Suthakar G and Srivastava RK: Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. Front Biosci 12: 5039-5051, 2007.